Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies…
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a…
AMSTERDAM, April 17, 2026 /PRNewswire/ -- OCI Global (Euronext: OCI) ("OCI" or the "Company") today announces that it has published the…
April 13, 2026 09:00 ET | Source: Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) --…
April 07, 2026 08:00 ET | Source: Valitor, Inc. BERKELEY, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company…
Shareholders approve all board-proposed agenda itemsCumulative voting, electronic general meetings and the revision of the quarterly dividend record date so…
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue…
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
Company Announcement no. 05/2026 Annual General Meeting 2026 Copenhagen, March 27, 2026 Annual General Meeting in cBrain A/SWednesday, April 29,…